Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.

[1]  D. Alberts,et al.  Phase III study of intraperitoneal cisplatin-intravenous cyclophosphamide versus intravenous cisplatin-intravenous cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG Intergroup study , 1996, International Journal of Gynecologic Cancer.

[2]  C. Cohen,et al.  A Phase I Trial of Cyclosphosphamide and Carboplatinum Combined with Interleukin-3 in Women with Advanced-Stage Ovarian Cancer , 1995 .

[3]  N. Mulder,et al.  Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Hittelman,et al.  Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Swenerton,et al.  Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Ozols,et al.  Mechanisms and modulation of resistance to chemotherapy in ovarian cancer , 1993, Cancer.

[7]  L. Kanz,et al.  Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  de Elisabeth G. E. Vries,et al.  Effects of interleukin-3 after chemotherapy for advanced ovarian cancer , 1992 .

[9]  D. Cruickshank,et al.  Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer , 1992, The Lancet.

[10]  A. Burgess,et al.  Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .

[11]  E. Vellenga,et al.  Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Ganser,et al.  Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. , 1992, Blood.

[13]  E. Eisenhauer,et al.  Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor , 1991 .

[14]  A. Ganser,et al.  Clinical Effects of Recombinant Human Interleukin‐3 , 1991, American Journal of Clinical Oncology.

[15]  D. Williams,et al.  Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  L. Park,et al.  Hematopoietic effects of a granulocyte‐macrophage colony‐stimulating factor/interleukin‐3 fusion protein , 1991, Cancer.

[17]  F. Wilcoxon.  Individual Comparisons by Ranking Methods , 1945 .

[18]  M. Deppe,et al.  Chemotherapy of gynecologic cancer , 1984 .